DAFTAR PUSTAKA

1. NKF–KDIGO. KDIGO 2017 clinical practice guideline update for diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). ISN. 2017; 7(1): 7.
2. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017; 389: 1238–52.
3. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–33.
4. Hager MR, Narla AD, Lisa T. Dyslipidemia in patient with chronic kidney disease. Rev Endocr Metab Disord. 2016; 18(1): 29–40.
5. Bowe B, Xie Y, Li T, Mokdad AH, Xian H. Changes in the US burden of chronic kidney disease from 2002 to 2016: an analysis of the global burden of disease study. JAMA. 2018.
6. Morton RL, Schlackow I, Mihaylova B, Staplin ND, Gray A, Cass A. The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review. Nephrol Dial Transplant. 2016; 31: 46–56.
7. Perhimpunan Nefrologi Indonesia (Pernefri). 11th Report Of Indonesian Renal Registry 2018. Pernefri. 2018;8:1–46.
8. Kementrian Kesehatan Republik Indonesia. Hasil riset kesehatan dasar tahun 2018. Litbangkes. 2018; 53: 1689–99.
9. Instalasi Rekam Medik RSUP Dr. M. Djamil Padang. Data rekam medik penyakit ginjal kronis 2015–September 2017 bagian rawat jalan dan rawat inap RSUP Dr. M. Djamil. Padang. 2017.
10. International Society of Nephrology. Chronic kidney disease. ISN Global Health Atlas. 2019.
11. Kuznik A, Mardekian J, Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an

analysis of national health and nutritional examination survey data, 2001-2010. BMC nephrology. 2013; 14: 132.

12. Rosenstein K, Tannock LR. Dyslipidemia in chronic kidney disease. NCBI. 2022.
13. Bauer F, Seibert FS, Rohn B, Babel N, Westhoff TH. Estimation of low density lipoprotein cholesterol in chronic kidney disease. Eurjpc. 2020: 1–7.
14. Aman AM, Soewondo P, Soelistijo SA, Arsana PM, Wismandari, Zufry H, et al. Pedoman pengelolaan dislipidemia di Indonesia. Jakarta: PB Perkeni. 2021.
15. Scicali R, Pino AD, Ferrara V, Urbano F, Piro S, Rabuazzo AM, et al. New trestment options for lipid lowering therapy in subjects with type diabetes. Acta diabetol. 2017.
16. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and strokee statistics-2017 update: a report from the american heart association. AHA Journals. 2017; 135(10):146–60.
17. Frostegard J. The role of PCSK9 in inflammation, immunity, and autoimmune diseases. Expert Rev Clin Immunol. 2021: 1–9.
18. Ference AB, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E. Low density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel. Eur Heart J. 2017: 1–14.
19. Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015; 161: 161–72.
20. Francois M, Colin B, Alberico LC, Konstantinos CK, Manuela C, Lina B, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019.
21. Ge P, Dong C, Ren X, Weiderpass E, Zhang C, Fan H, et al. The high prevalence of low-HDL-cholesterol levels and dyslipidemia in rural populations in northwestern China. PLoS One. 2015;10(2):1–5.
22. Maduka IC, Neboh EE, Ufelle SA. The relationship between serum cortisol, adrenaline, blood glucose, and lipid profile of undergraduated students under examination stress. African Health Sciences. 2015; 15(1): 1–4.

23. Russi G. Severe dyslipidemia in pregnancy: the role of therapeutikc apheresis. Transfus Apher. 2015: 1–5.
24. Duntas LH, Brenta G. A renewed focus on the association between thyroid hormones and lipid metabolism. Front Endocrinol. 2018; 511 (9): 1–10.
25. Liu HH, Li JJ. Aging and dyslipidemia: a review of potential mechanisms. Ageing Res Rev. 2015; 19: 43–52.
26. Chrostek L, Supranowicz, Panasiuk A, Cylwik B, Gruszweska E, Flisiak R. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med. 2013: 1–5.
27. Noviyanti F, Decroli E, Sastri S. Perbedaan kadar LDL-kolesterol pada pasien diabetes melitus tipe 2 dengan dan tanpa hipertensi di RS Dr. M. Djamil Padang tahun 2011. J Kesehat Andalas. 2015; 4(2): 545–50.
28. Shrestha P, van de Sluis B, Dullaart RPF, van den Born J. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell Signal. 2019; 55: 53–64.
29. Spolitu S, Dai W, Zadroga JA, Ozcan L. PCSK9 and lipid metabolism. Curr Opin Lipidol. 2019;30(3):186–91.
30. Burnett JR, Hooper AJ. PCSK9 - a journey to cardiovascular outcomes. N Engl J Med. 2018;379(22):2161–2.
31. Schulz R. Schluter KD. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol. 2015; 110: 4.
32. Maliglowka M, Kosowski M, Hachula M, Cyrnek M, Buldak L, Basiak M, et al. Insight into the envolving role of PCSK9. Metabolites. 2022; 256 (12): 1–25.
33. Caselli C, Turco SD, Ragusa R, Lorenzoni V, Graaf MD, Basta G, et al. Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. Cardiovasc Diabetol. 2019;18:1–12.
34. Konarzewski M, Szolkiewics M, Sucatjtys-Szule E. Elevated circulating PCSK9 consentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol. 2014 40(2):157–63.

35. Abujrad H, Mayne J, Ruzicka M, Cousin M, Raymond A, Cheesman J, et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis. 2014; 233: 123–9.
36. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanism, and potential consequences. Am J Physiol Renal Physiol. 2006; 290(2): 262–72.
37. Dounousi E, Tellis C, Pavlakou P, Duni A, Liakopoulos V, Mark PB, et al. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. Oxid Med Cell Longev. 2021: 1–8.
38. Rogacev KS, Heine GH, Silbernagel G. PCSK9 plasma concentrations are independent of GFR and do not predict cardiovascular events in patients with decreased GFR. PLoS One. 2016; 11(1).
39. Morena M, May LC, Chenine L, Arnaud L, Dupuy AM, Pichelin M, et al. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: relationship with glomerular filtration rate and lipid metabolism. J Clin Lipidol. 2017; 11(1): 87–93.
40. Liu A, Frostegard J. PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. J Intern Med. 2018; 284 (2): 193–210.
41. Shapiro MD, Tavori H, Fazio S. PCSK9: from basic science discoveries to clinical trials. Circ Res. 2018;122(10):1420–38.
42. Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Boren J, et al. 2017 Update of ESC/EAS taskforce on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2017: 1–3.
43. Robinson JG, Huijgen R, Ray K, Persons J, Kastelein JJ, Pencina MJ. Determining when to add nonstatin therapy: a quantitative approach. J am Coll Cardiol. 2016; 68: 2412–21.

44. Suwitra K. Penyakit ginjal kronik. Dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF (editor). Buku Ajar Ilmu Penyakit Dalam. Edisi ke–6. Jakarta : Pusat Penerbitan Ilmu Penyakit Dalam. 2014: 1035–40.
45. Perhimpunan Nefrologi Indonesia (Pernefri). Annual Report of Indonesian Renal Registry. Pernefri. 2015; 8: 1–45.
46. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. Am J Med. 2016;129(2):153–62.
47. NKF–KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. ISN. 2012; 3(1): 5–14.
48. Vinodh KB, Mohan T. Retrospective comparison of estimated GFR using 2006 MDRD, 2009 CKD-EPI and cockcroft-gault with 24 hour urine creatinine clearance. J Clin Diagnostic Res. 2017;11(5): 9–12.
49. Singh S, Pathak AK, Parappanavar NU. A study of fasting lipid profile in chronic kidney disease patients. Int J Res Med Sci. 2019; 7: 2282–5.
50. Lousa I, Reis F, Beirao I, Alves R, Belo L, Santos-Silva A. New potential biomarkers for chronic kidney disease management-A review of the literature. Int J Mol Sci. 2021;22(1):1–37.
51. Yang J, He W. Chronic kidney disease : diagnosis and treatment. Nature. 2020.
52. Kovesdy CP, Furth SL, Zoccali C. Obesity and kidney disease: hidden consequences of the of the epidemic. Can J Kidney Health Dis. 2017; 4: 1–10.
53. Wong E. Chronic kidney disease. Lancet. 2012; 379(8911): 165–80.
54. Tang X, Lieske JC. Acute and chronic kidney injury in nephrolithiasis. Curr Opin Nephrol Hypertens. 2014; 23(4): 385–90.
55. Arnold M, Pandeya N, Byrnes G. Global burden of cancer attributable to high body-mass index in 2012: a population based study. Lancet Oncol. 2015; 16: 36–46.
56. Seidah NG. New Developments in proprotein convertase subtilisin–kexin 9's biology and clinical implications. Curr Opin Lipidol. 2016;27:274–81.

57. Pavlakou P, Liberopoulos E, Dounousi E, Elisaf M. PCSK9 in chronic kidney disease. Int Urol Nephrol. 2017: 1–10.
58. Guo Y, Yan B, Tai S, Zhou S, Zheng XL. PCSK9: Associated with cardiac diseases and their risk factors?. Arch Biochem Biophys. 2021; 704: 108717.
59. Konarzewski M, Szolkiewicz M, Sucajtys-Szule E. Elevated circulating PCSK9 consentration in renal failure patients is corrected by renal replacement therapy. Am J Nephrol. 2014; 40(2): 157–63.
60. Tang ZH, Li TH, Peng J. PCSK9: a novel inflammation modulator in atherosclerosis. J Cell Physiol.2019; 234 (3): 2345–55.
61. Duni A, Liakopoulos V, Rapsomanikis KP, Dounousi E. Chronic kidney disease and disproportionally increased cardiovascular damage: does oxidative stress explain the burden?. Oxid Med Cell Longev. 2017: 15.
62. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med.2018; 379(22): 2097–107.
63. Liberopoulos E. Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: an unsolved mystery. Eur J Prev Cardiol. 2020.
64. Stralberg T, Nordenskjold A, Cao Y, Kublickiene K, Nilsson E. Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis. Eur J Clin Invest. 2019: 49 (7).
65. Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5(12):941–50.
66. Medina F. Alirocumab: mechanism of action, pharmacokinetics, safety, and clinical outcomes. Indones J Pharm. 2020 Feb; 5(1): 7–11.
67. Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018; 57(7): 769–79.

68. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ ACC/ AACVPR/ AAPA/ ABC/ ACPM/ ADA/ AGS/ APhA/ ASPC/ NLA/ PCNA Guideline on the management of blood cholesterol: executive summary: a report of the american college of cardiology/american heart association task Force on clinical practice guidelines. Circ. 2019; 139(25): 1046–81.
69. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. GAUSS-3 investigators. efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90.
70. Vallejovaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, et al. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019; 288:85–93.
71. Filippatos TD, Filippas NS, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS. PCSK9 and carbohydrate metabolism: A double-edged sword. World J Diabetes. 2017;8(7):311–16.
72. Gurgoze MT, Muller-Hansma AH, Schreuder MM, Galema-Boers AM, Boersma E. Adverse Events Associated With PCSK 9 Inhibitors: A Real-World Experience. Clin Pharmacol Ther. 2019;105(2):496–504.
73. Vaziri, N. D. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016; 90: 41-52.
74. Jacobson AT, Ito KM, Maki CK. National lipid association (NLA) recommendation for patient-centered management of dyslipidmeia: part 1 (full report). J Clin Lipid. 2015; 9: 129–69.
75. Feingold KR, Anawalt B, Boyce A. Introduction to lipids and lipoproteins. NIH. 2021: 1–42.
76. Nugraha G, Edijanto SP. Penentuan Formula untuk menetapkan kolesterol LDL. Med Health Sci J. 2018; 2(2): 33–8.

77. Legoretta V, Chavez-sanchez L, Chavez-rueda K, Blanco F, The innate immune response mediated by TLRs in atherosclerosis in inflamation, chronic disease and cancer molecular biology, imunology, and clinical bases. InTech; 2014: 53–74.
78. Wild R, Weedin EA, Wilson D. Dyslipidemia in Pregnancy. Endocrin Metab Clin N Am. 2016; 45: 55–63.
79. Yanai H, Yoshida H. Secondary dyslipidemia: its treatments and association with atherosclerosis. Glob Adv Health Med. 2021; 3(1):15–23.
80. Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC. Insulin resistentance in patients with Chronic Kidney Disease. Journal Biotechnol Biomed. 2012: 1–12.
81. Praramdhan TA, Yakub K, Oswari LD. Perbedaan kadar profil lipid pasien penyakit ginjal diabetik dan non-diabetik yang menjalani hemodialisis. MKS. 2017; 49(2): 93–9.
82. Khatiwada S, Rajendra KC, Gautam S, Lamsal M, Baral N. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients. Clinical Diabetes and Endocrinology. 2016; 2(3): 1–5.
83. Tjekyan RMS. 2014. Prevalensi dan faktor risiko penyakit ginjal kronik di RSUP Dr. Mohammad Hoesin Palembang tahun 2012. MKS. 2014; 46(4): 276–81.
84. Centers for Disease Control and Prevention. Chronic kidney disease surveillance system. 2021.
85. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nrneph. 2018: 1–14.
86. Levenson AE, Shah AS, Khoury PR, Kimball TR, Urbina EM, Ferranti SD, et al. Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. Pediatr Diabetes. 2017; 18(8): 755–60.
87. Ooi TC, Raymond A, Cousins M, Faveau C, Taljaard M, Gavin C, et al. Relationship between testosterone, estradiol and circulating PCSK9: Cross-sectional and interventional studies in humans. Clinica Chimica Acta. 2015; 446: 97–104.

88. Saini M, Vamne A, Kumar W, Chandel MS. The study of pattern of lipid profile in chronic kidney disease patients on conservative management and hemodialysis: a comparative study. Cureus. 2022; 14(1):1–5.
89. Adejumo OA, Okaka EI, Ojugwu LI. Lipid profile in pre dyalisis chronic kidney disease patients in southern Nigeria. Ghana Med J. 2016; 50: 44-9.
90. Kumari KR, Srinivas B. Study of lipid profile in patients with chronic kidney disease on conservative management and hemodialysis. Int J Sci Stud. 2018; 6: 108–13.
91. Singh S, Pathak AK, Parappanavar NU. A study of fasting lipid profile in chronic kidney disease patients. Int J Res Med Sci. 2019; 7(6): 2282–5.
92. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metabol. 2009;94:2537–43.
93. Alfano G, Perrone R, Fontana F, Ligabue G, Giovanella S, Ferrari A, et al. Rethinking chronic kidney disease in the aging population. MDPI life. 2022; 1724 (12): 1–18.
94. Chen HM, Wen W, Yong CG, Yi DZ, Hong LX, Zhi HL, et al. The ralationship between obesity and diabetic nephropaty in China. BMC Nephropaty. 2013; 14: 69–75.
95. Pinto KRD, Feckinghaus CM, Hirakata VN. Obesity as a predictive factor for chronic kidney disease in adults: systematic review and meta-analysis. Braz J Med Biol Res. 2021; 54(4): 1–10.
96. Fillipatos TD, Liberopoulos E, Georgoula M, Tellis CC, Tselepis AD, Elisaf M. Effects of increased body weight and short-term weight loss serum PCSK9 levels – a prospective pilot study. Arc Med Atheroscler Dis. 2017; 2: 46–51.
97. Lokesh S, Kadavanu TM, Green SR. A comparative study of lipid profile and cardiovascular risk biomarkers among chronic haemodialysis patients and healthy individuals. J Clin Diagn Res. 2016; 10(9): 1–5.
98. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabol. 2014; 63: 1469-79.

99. Senge CE, Moeis ES, Sugeng CE. Hubungan kadar lipid serum dengan nilai estimasi laju filtrasi glomerulus pada penyakil ginjal kronik. Jurnal e-Clinic. 2017; 5(1): 45–50.
100. Liu P, Quin RR, Lam NN, Al-Wahs H, Sood MM, Tangri N, et al. Progression and regression of chronic kidney disease by age among adults in a population-based cohort in alberta, canada. JAMA. 2021;4(6): 1–13.
101. Macrae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in scottish primary care. Br J Gen Pract. 2021: 243–9.
102. Fasipe OJ, Akhideno PE, Owhin SO, Ilukho FA, Fasipe OB. The comorbity profile among chronic kidney disease patients in clinical practice: a prospective study. Int Arch Health Sci. 2023; 6(1): 46–51.
103. Feingold KR, Grunfeld C. The effect of inflammation and infection on lipids and lipoproteins. NIH. 2022: 11–14.
104. Chou CY, Wang SM, Liang CC, Chang CT, Liu JH, Wang IK, et al. Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings. MDJ. 2014; 93 (27): 1–4.
105. Hidayat R, Azmi S, Pertiwi D. Hubungan kejadian anemia dengan penyakit ginjal kronik pada pasien yang dirawat di bagian ilmu penyakit dalam RSUP Dr. M. Djamil Padang tahun 2010. J Kesehat Andalas. 2016; 5(3): 546–50.
106. Chowta N, Reddy S, Chowta M, Shet A, Basavaprabhu A, Madi D. Lipid profile in anemia: Is there any correlation?. ASJC. 2017; 10(4): 837–40.
107. Shalev H, Kapelushnik J, Moser A, Knobler H, Tamary H. Hypocholesterolemia in chronic anemia with increased erythropoietic activity. American J Hem. 2007; 82: 199–202.
108. Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K. An update on the pathophysiology and treatment of cardiorenal syndrome. Cardiol Res. 2020;11(2):76.
109. Ronco C, Lullo LD. Cardiorenal syndrome in Western countries: Epidemiology, diagnosis and management approaches. Kidney Dis. 2016;2(4):151–63.

110. Connell AW, Sowers JR. The cardiorenal metabolic syndrome. J Am Soc Hypertens. 2014; 8(8): 604–6.
111. Hwang HS, Kim JS, Kim YG, Lee SY, Ahn SY, Lee HJ, et al. Circulating PCSK9 level and risk of cardiovascular events and death in hemodialysis patients. J Clin Med. 2020; 24(9): 1–11
112. Kajingulu FP, Lepira FB, Nkodia AN, Makulo JR, Mokoli VM, Ekulu PM. Circulating proprotein convertase subtilisin/kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black africans patients. BMC Nephrology. 2022; 123(23): 1–11.
113. Jin K, Park BS, Kim YW, Vaziri ND. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014; 63(4): 584–9.
114. Cui Q, Ju X, Yang T, Zhang M. Serum PCSK9 is associated with multiple metabolic factors in a large han chinese population. Atherosclerosis. 2010; 213(2): 632–6.
115. Persson L, Cao G, Stahle L, Sjoberg BG, Troutt JS, Konrad RJ, et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol. 2010;30:2666–72.
116. Zemaitis MR, Foris LA, Katta S, Bashir K. Uremia. Stat Pearls. 2022; 15–50.
117. Kullawong N, Apidechkul T, Upala P, Tamompark R, Keawdounglek V, Wongfu C, et al. Factors associated with elevated low density lipoprotein cholesterol levels among hill tribe people aged 30 years and over in Thailand: a cross-sectional study. BMC Public Health. 2021; 21(498): 1–10.
118. Schoeneck M, Iggman D. The effect of foods on LDL cholesterol levels: a systematic review of the accumulated evidance from systematic reviews and metaanalyses of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021; 31: 1325–38.